|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-4-4
|
|
pubmed:abstractText |
Homoharringtonine (HHT) has antileukemic activity in patients with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML). Combinations of HHT, interferon-alpha (IFN-alpha), and cytarabine (ara-C) have been studied in various CML phases. The objectives of this study were to evaluate the efficacy and toxicity profiles of a combination regimen of simultaneous HHT and IFN-alpha therapy in patients with chronic-phase CML who were not exposed previously to either agent.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:AndreeffMichaelM,
pubmed-author:BethMaryM,
pubmed-author:CortesJorgeJ,
pubmed-author:FaderlStefanS,
pubmed-author:Garcia-ManeroGuillermoG,
pubmed-author:GilesFrancis JFJ,
pubmed-author:KantarjianHagop MHM,
pubmed-author:KeatingMichaelM,
pubmed-author:KollerCharlesC,
pubmed-author:KornblauSteveS,
pubmed-author:MallardSusieS,
pubmed-author:MurgoAnthonyA,
pubmed-author:O'BrienSusanS,
pubmed-author:ShanJianqinJ,
pubmed-author:TalpazMosheM,
pubmed-author:ThomasDeborahD
|
|
pubmed:copyrightInfo |
Copyright 2002 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2024-32
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11932905-Adult,
pubmed-meshheading:11932905-Aged,
pubmed-meshheading:11932905-Anemia,
pubmed-meshheading:11932905-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11932905-Dose-Response Relationship, Drug,
pubmed-meshheading:11932905-Female,
pubmed-meshheading:11932905-Follow-Up Studies,
pubmed-meshheading:11932905-Harringtonines,
pubmed-meshheading:11932905-Humans,
pubmed-meshheading:11932905-Interferon-alpha,
pubmed-meshheading:11932905-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:11932905-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:11932905-Male,
pubmed-meshheading:11932905-Middle Aged,
pubmed-meshheading:11932905-Prognosis,
pubmed-meshheading:11932905-Risk Factors,
pubmed-meshheading:11932905-Survival Rate
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
|
|
pubmed:affiliation |
Department of Leukemia and Bioimmunotherapy, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
